Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?

Table 1 Randomized controlled trials of neoadjuvant radiotherapy versus surgery alone for esophageal squamous cell carcinoma

Study	Histology	SCC (%)	Treatment	n	MS (months)	5-year OS (%)	P value
Launois and colleagues [11]	SCC	100	NART 40 Gy	77	10	10	NS
			Surgery	57	12	12
Gignoux and colleagues [12]	SCC	100	NART 33 Gy	106	11	11	NS
			Surgery	102	11	10
Arnott and colleagues [13]	AC/SCC	36	NART 20 Gy	90	8	9	NS
			Surgery	86	8	17
Nygaard and colleagues [14]	SCC	100	NART 35 Gy	48		21^a	NS
			Surgery	41		9^a
Wang and colleagues [15]	SCC	100	NART 40 Gy	104		35	NS
			Surgery	102		30

^aThree-year overall survival (OS). AC adenocarcinoma, MS median survival, NART neoadjuvant radiotherapy, NS not significant, SCC squamous cell carcinoma.

ISSN: 1477-7819